Adam’s Biotech Scorecard: Novartis’ MorphoSys boondoggle
This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.
Boston-area beaches are closed to dogs starting May 1, so Bo got one last chance this past weekend to dig and play in the sand. Pssst: You can sneak your dog to Wingaersheek Beach on summer nights, after the parking monitors leave at 5 p.m. Go to the far end, where Gloucester residents hang out. Also, dog swimming at the middle reservoir in the Winchester Fells is a forbidden joy. Just don’t rat me (or Bo) out. Get in touch: [email protected].
Novartis’ $3 billion MorphoSys boondoggle
Oh man, there I go. Sorry, I can’t help myself. I’m fascinated by the very real possibility that Novartis, one of the largest and most successful pharma companies in the world, is on the cusp of burning $3 billion of its cash in a furnace.
Get unlimited access to award-winning journalism and exclusive events.
